| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 11,400 | 11,700 | 12:46 | |
| 11,200 | 12,000 | 24.10. |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Syndax Pharmaceuticals Inc - 8-K, Current Report | ||
| Fr | FDA approves Syndax's Revuforj for second leukemia indication | ||
| Fr | Syndax Pharmaceuticals, Inc.: Syndax Announces FDA Approval of Revuforj (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia | - First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation - - Second approved indication for Revuforj in... ► Artikel lesen | |
| Fr | Syndax gains additional indication for Revuforj in acute myeloid leukemia | ||
| Fr | XFRA 1T3: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSYNDAX PHARMACEU.DL-... ► Artikel lesen |
